Molecular Diagnostic Detects and Discriminates Influenza A and B Viruses

The analyzer automatically executes all the required assay steps and reports test results on a built-in touch screen. No manual reagent addition, operator intervention, or data interpretation is required.

Currently, near-patient influenza testing is performed using rapid immunoassays. However, studies have shown that such immunoassays have a sensitivity of only 10% to 70%. The Liat Influenza A/B assay has equivalent or better sensitivity and specificity as current lab-based nucleic acid tests, while substantially matching the time-to-result and ease-of-use of rapid immunoassays.

IQuum, Inc. has received the US Food and Drug Administration (FDA; Silver Spring, MD, USA) 510(k) clearance to market the Liat Influenza A/B assay and the Liat analyzer. The assay and analyzer are also available as a CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices.

Related Links:
IQuum
US Food and Drug Administration